Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has completed its previously announced acquisition of Avedro, Inc. (Nasdaq: AVDR)
Read MoreGlaukos and Avedro announce definitive acquisition agreement under which Glaukos will acquire Avedro in an all-stock transaction
Read MoreHealthQuest portfolio company Avedro, Inc. (Nasdaq: AVDR), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share, for total gross proceeds of $70.0 million.
Read MoreHealthQuest Capital portfolio company Avedro, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations.
Read MoreAvedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners.
Read More
